In this article, we will be taking a look at the 5 Best Healthcare Stocks to Buy According to Wall Street Analysts. If you wish to see the complete list, visit 10 Best Healthcare Stocks to Buy According to Wall Street Analysts.
5. UniQure N.V. (NASDAQ:QURE)
Price Target Upside: 36.29%
UniQure N.V. (NASDAQ:QURE) is among the best healthcare stocks.
TheFly reported on June 18 that Barclays raised its rating on QURE to Overweight from Equal Weight and increased its price target to $65 from $25. The firm viewed QURE’s planned Biologics License Application (BLA) submission for Huntington’s disease in the third quarter as a significant positive catalyst. Barclays also improved its probability assessment for the program’s success and highlighted the potential value of Huntington’s disease opportunity, estimating substantial upside for shares based on the possibility of a multibillion-dollar peak sales opportunity.
Separately, on June 19, UniQure N.V. (NASDAQ:QURE) announced preliminary six-month follow-up findings from the initial low-dose group of its ongoing Phase I/IIa study evaluating AMT-260, an investigational gene therapy for refractory mesial temporal lobe epilepsy. Data from the six participants showed that three patients experienced notable reductions in disabling seizures during months four through six, with decreases ranging from 79% to complete reduction compared with baseline. The remaining patients showed mixed seizure changes during the follow-up period. No serious adverse events linked to AMT-260 or the surgical procedure were reported, and observed side effects were mild to moderate, with headache being the most common. Enrollment continues in a higher-dose cohort.
UniQure N.V. (NASDAQ:QURE) is a biopharmaceutical company developing one-time AAV-based gene therapies for severe genetic and central nervous system diseases, aiming to deliver potentially curative treatments.
4. Edgewise Therapeutics, Inc. (NASDAQ:EWTX)
Price Target Upside: 41.10%
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is among the best healthcare stocks.
TheFly reported on June 17 that RBC Capital increased its price target for EWTX to $59 from $48 while maintaining an Outperform rating on the shares. The firm highlighted the company’s 12-week results from the ‘7500 HCM trial, noting that the data demonstrated encouraging safety and efficacy outcomes. RBC Capital believes the findings could support a future Phase 3 trial design without the need for titration echocardiograms, potentially improving the therapy’s usability in real-world settings. The firm also emphasized EWTX’s broader cardiology opportunity, citing the potential of ‘7500 and the company’s pipeline to support significant long-term growth.
Earlier this month, on June 1, Edgewise Therapeutics, Inc. (NASDAQ:EWTX) announced a definitive agreement with Servier for the acquisition of sevasemten and its muscular dystrophy business for $1.55 billion in upfront cash and up to $1.1 billion in additional milestone payments, representing potential total consideration of $2.65 billion. The transaction strengthens EWTX’s financial position and allows the company to focus its strategy on advancing its cardiovascular pipeline. Following the deal, Edgewise will shift into a cardiovascular-focused company, with programs including EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF, and EDG-003. The company plans to continue progressing its cardiovascular development programs using the enhanced financial flexibility.
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is a clinical-stage biopharmaceutical company developing precision oral medicines for severe muscle diseases, using a unique approach focused on protecting skeletal and cardiac muscles from damage.
3. ResMed Inc. (NYSE:RMD)
Price Target Upside: 45.43%
ResMed Inc. (NYSE:RMD) is among the best healthcare stocks.
TheFly reported on June 22 that KeyBanc adjusted its price target for RMD to $266 from $290 while maintaining an Overweight rating on the shares. The firm noted that insights from the SLEEP APSS Meeting in Baltimore, along with further analysis of the obstructive sleep apnea (OSA) competitive environment, strengthened its confidence in ongoing patient demand trends. KeyBanc highlighted continued momentum in the OSA and CPAP markets, supported by increasing demand growth from factors such as GLP-1 adoption and consumer wearable technologies.
Earlier, on June 1, ResMed Inc. (NYSE:RMD) completed its acquisition of Noctrix Health, Inc., a medical device company focused on wearable therapies for chronic neurological conditions. The transaction expands ResMed’s sleep health portfolio into the treatment of Restless Legs Syndrome (RLS), addressing an area with significant unmet medical needs. Noctrix’s Nidra TOMAC Therapy, an FDA De Novo classified, non-invasive treatment, is designed to help reduce symptoms of moderate-to-severe RLS and improve sleep quality for adults with limited treatment options. Through the acquisition, RMD aims to integrate Noctrix’s technology into its connected health ecosystem, strengthening its focus on improving patient outcomes and expanding access to innovative home-based care solutions.
ResMed Inc. (NYSE:RMD) is a global digital health and medical device company specializing in sleep apnea, respiratory care, and connected healthcare solutions across more than 140 countries.
2. Legend Biotech Corporation (NASDAQ:LEGN)
Price Target Upside: 104.50%
Legend Biotech Corporation (NASDAQ:LEGN) is among the best healthcare stocks.
TheFly reported on June 3 that UBS increased its price target on LEGN to $49 from $31 while reiterating a Buy rating on the stock. The firm cited promising early clinical findings from the company’s LB5006 program, noting evidence of therapeutic activity at the higher dose level. UBS also highlighted the treatment’s favorable initial safety observations, which contributed to its positive outlook on the program’s development potential.
Moreover, on June 14, Legend Biotech Corporation (NASDAQ:LEGN) reported initial clinical proof-of-concept results for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T therapy for relapsed or refractory B-cell non-Hodgkin lymphoma. Data from an ongoing Phase 1 study showed that a single infusion produced dose-related CAR-T cell expansion without requiring lymphodepletion. At the higher dose level, the therapy delivered a 100% objective response rate and an 83.3% complete response rate, with all responses remaining active at the data cutoff date.
LB2501 also demonstrated a favorable tolerability profile, with no dose-limiting toxicities, serious adverse events, neurotoxicity events, or treatment-related deaths reported. The findings support the potential of the company’s in vivo CAR-T platform and further advancement of the program.
Legend Biotech Corporation (NASDAQ:LEGN) is a commercial-stage biopharmaceutical company developing and manufacturing innovative cell therapies, with a strong focus on CAR-T treatments for cancer.
1. Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Price Target Upside: 108.84%
Ocular Therapeuticx, Inc. (NASDAQ:OCUL) is among the best healthcare stocks.
TheFly reported on June 18 that H.C. Wainwright increased its price target on OCUL to $25 from $21 while maintaining a Buy rating on the stock. The firm’s updated outlook followed the company’s discussion of feedback received during a recent Type C meeting with the FDA at its investor day event. H.C. Wainwright indicated that the regulatory update strengthened confidence in Axpaxli’s commercial potential, leading to higher projections for peak annual revenue and an improved assessment of the therapy’s likelihood of obtaining regulatory approval. The firm also noted expectations for strong physician uptake and broad market penetration following a potential launch.
A significant corporate development occurred on June 17, when Ocular Therapeuticx, Inc. (NASDAQ:OCUL) outlined its regulatory strategy for AXPAXLI in wet age-related macular degeneration. The company announced plans to submit a New Drug Application in the fourth quarter of 2026 using efficacy and safety results from the SOL-1 trial alongside interim safety findings from SOL-R. OCUL also revised the SOL-R study design to continue evaluating additional endpoints through Week 96 and further differentiate AXPAXLI from existing treatments. In addition, the company streamlined its non-proliferative diabetic retinopathy development program by concentrating resources on the Phase 3 HELIOS-3 trial.
Ocular Therapeuticx, Inc. (NASDAQ:OCUL) is a biopharmaceutical company developing sustained-release therapies for retinal and eye diseases, using its proprietary hydrogel technology to deliver medication directly to the eye.
While we acknowledge the potential of OCUL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than OCUL and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Most Promising Penny Stocks According to Wall Street Analysts and 10 Best Growth Stocks Under $20 to Buy.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
